Cantor Fitzgerald Weighs in on Thermo Fisher Scientific Inc.’s FY2017 Earnings (TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Cantor Fitzgerald issued their FY2017 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a report released on Friday. Cantor Fitzgerald analyst B. Brokmeier expects that the medical research company will post earnings of $9.23 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $194.00 target price on the stock.
Several other equities research analysts have also weighed in on TMO. Jefferies Group LLC cut their target price on shares of Thermo Fisher Scientific from $163.00 to $160.00 and set a “hold” rating on the stock in a report on Monday, January 23rd. Evercore ISI increased their target price on shares of Thermo Fisher Scientific from $160.00 to $162.00 and gave the stock a “buy” rating in a report on Tuesday, January 31st. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a report on Wednesday, February 1st. Leerink Swann set a $187.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, April 27th. Finally, Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 26th. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $182.67.
Thermo Fisher Scientific (NYSE:TMO) opened at 171.53 on Monday. Thermo Fisher Scientific has a 52-week low of $139.07 and a 52-week high of $173.53. The firm’s 50-day moving average is $162.20 and its 200 day moving average is $152.72. The stock has a market capitalization of $67.11 billion, a PE ratio of 31.29 and a beta of 1.10.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $2.08 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.06. Thermo Fisher Scientific had a net margin of 11.06% and a return on equity of 15.41%. The firm had revenue of $4.77 billion for the quarter, compared to analysts’ expectations of $4.68 billion. During the same period in the previous year, the company posted $1.80 EPS. The company’s quarterly revenue was up 10.9% compared to the same quarter last year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, July 17th. Investors of record on Thursday, June 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Tuesday, June 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 11.79%.
In related news, insider Thomas W. Loewald sold 1,532 shares of the firm’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $168.76, for a total value of $258,540.32. Following the completion of the transaction, the insider now owns 41,277 shares of the company’s stock, valued at $6,965,906.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Seth H. Hoogasian sold 3,142 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $158.71, for a total transaction of $498,666.82. Following the completion of the transaction, the vice president now directly owns 31,104 shares of the company’s stock, valued at approximately $4,936,515.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,964 shares of company stock valued at $9,215,579. 0.52% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Investors Inc. PA increased its position in Thermo Fisher Scientific by 14.7% in the fourth quarter. Federated Investors Inc. PA now owns 9,431 shares of the medical research company’s stock worth $1,331,000 after buying an additional 1,210 shares during the period. Cornercap Investment Counsel Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $2,865,000. Tredje AP fonden increased its position in Thermo Fisher Scientific by 4.9% in the fourth quarter. Tredje AP fonden now owns 39,367 shares of the medical research company’s stock worth $5,561,000 after buying an additional 1,834 shares during the period. Fiera Capital Corp increased its position in Thermo Fisher Scientific by 32.9% in the fourth quarter. Fiera Capital Corp now owns 157,543 shares of the medical research company’s stock worth $22,230,000 after buying an additional 38,959 shares during the period. Finally, Chevy Chase Trust Holdings Inc. increased its position in Thermo Fisher Scientific by 1.8% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 338,114 shares of the medical research company’s stock worth $51,935,000 after buying an additional 5,944 shares during the period. 87.80% of the stock is owned by institutional investors and hedge funds.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.